Transfusion medicine as of 2014
Transfusion of blood components is one of the most common medical treatments, and in spite of the time that has evolved since we started to transfuse blood routinely in the 1930s, there are issues associated with its use that we are still trying to improve. Issues such as when to transfuse and adver...
Main Authors: | , |
---|---|
Format: | Online |
Language: | English |
Published: |
Faculty of 1000 Ltd
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229729/ |
id |
pubmed-4229729 |
---|---|
recordtype |
oai_dc |
spelling |
pubmed-42297292015-01-09 Transfusion medicine as of 2014 Lozano, Miguel Cid, Joan Review Article Transfusion of blood components is one of the most common medical treatments, and in spite of the time that has evolved since we started to transfuse blood routinely in the 1930s, there are issues associated with its use that we are still trying to improve. Issues such as when to transfuse and adverse effects associated with the transfusion are fields where new evidence is being generated that ideally should help us to indicate when and what to transfuse to the patients. The recognition that the evidence generated in randomized control trials was not widely applied to guide the indication of the transfusion of blood components has provoked the development of initiatives that try to reduce its unnecessary usage. Those initiatives, grouped under the name of patient blood management, have represented a significant paradigm change, and a growing number of activities in this field are performed in health-care facilities around the world. This article tries to summarize the latest publications in those fields. Faculty of 1000 Ltd 2014-11-04 /pmc/articles/PMC4229729/ /pubmed/25580259 http://dx.doi.org/10.12703/P6-105 Text en © 2014 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
repository_type |
Open Access Journal |
institution_category |
Foreign Institution |
institution |
US National Center for Biotechnology Information |
building |
NCBI PubMed |
collection |
Online Access |
language |
English |
format |
Online |
author |
Lozano, Miguel Cid, Joan |
spellingShingle |
Lozano, Miguel Cid, Joan Transfusion medicine as of 2014 |
author_facet |
Lozano, Miguel Cid, Joan |
author_sort |
Lozano, Miguel |
title |
Transfusion medicine as of 2014 |
title_short |
Transfusion medicine as of 2014 |
title_full |
Transfusion medicine as of 2014 |
title_fullStr |
Transfusion medicine as of 2014 |
title_full_unstemmed |
Transfusion medicine as of 2014 |
title_sort |
transfusion medicine as of 2014 |
description |
Transfusion of blood components is one of the most common medical treatments, and in spite of the time that has evolved since we started to transfuse blood routinely in the 1930s, there are issues associated with its use that we are still trying to improve. Issues such as when to transfuse and adverse effects associated with the transfusion are fields where new evidence is being generated that ideally should help us to indicate when and what to transfuse to the patients. The recognition that the evidence generated in randomized control trials was not widely applied to guide the indication of the transfusion of blood components has provoked the development of initiatives that try to reduce its unnecessary usage. Those initiatives, grouped under the name of patient blood management, have represented a significant paradigm change, and a growing number of activities in this field are performed in health-care facilities around the world. This article tries to summarize the latest publications in those fields. |
publisher |
Faculty of 1000 Ltd |
publishDate |
2014 |
url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229729/ |
_version_ |
1613155773773250560 |